- Home
- BCDA vs ARTW Comparison
BCDA vs ARTW Comparison
Compare BCDA & ARTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ARTW
- Stock Information
- Founded
- BCDA N/A
- ARTW 1956
- Country
- BCDA United States
- ARTW United States
- Employees
- BCDA N/A
- ARTW N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ARTW Industrial Machinery/Components
- Sector
- BCDA Health Care
- ARTW Industrials
- Exchange
- BCDA Nasdaq
- ARTW Nasdaq
- Market Cap
- BCDA 7.9M
- ARTW 7.8M
- IPO Year
- BCDA N/A
- ARTW N/A
- Fundamental
- Price
- BCDA $2.18
- ARTW $1.81
- Analyst Decision
- BCDA Strong Buy
- ARTW
- Analyst Count
- BCDA 1
- ARTW 0
- Target Price
- BCDA $25.00
- ARTW N/A
- AVG Volume (30 Days)
- BCDA 52.4K
- ARTW 633.7K
- Earning Date
- BCDA 11-13-2024
- ARTW 02-26-2025
- Dividend Yield
- BCDA N/A
- ARTW N/A
- EPS Growth
- BCDA N/A
- ARTW N/A
- EPS
- BCDA N/A
- ARTW N/A
- Revenue
- BCDA $71,000.00
- ARTW $25,181,639.00
- Revenue This Year
- BCDA N/A
- ARTW N/A
- Revenue Next Year
- BCDA N/A
- ARTW N/A
- P/E Ratio
- BCDA N/A
- ARTW N/A
- Revenue Growth
- BCDA N/A
- ARTW N/A
- 52 Week Low
- BCDA $1.63
- ARTW $1.33
- 52 Week High
- BCDA $8.85
- ARTW $4.15
- Technical
- Relative Strength Index (RSI)
- BCDA 49.10
- ARTW 49.49
- Support Level
- BCDA $2.05
- ARTW $1.60
- Resistance Level
- BCDA $2.36
- ARTW $2.21
- Average True Range (ATR)
- BCDA 0.21
- ARTW 0.41
- MACD
- BCDA -0.00
- ARTW -0.05
- Stochastic Oscillator
- BCDA 46.43
- ARTW 8.24
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world-wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.